Your browser doesn't support javascript.
loading
The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives.
Barreto, Joaquim; Campos-Staffico, Alessandra M; Nadruz, Wilson; Quinaglia, Thiago; Sposito, Andrei C.
Afiliação
  • Barreto J; Laboratory of Atherosclerosis and Vascular Biology, University of Campinas (Unicamp), Campinas, Sao Paulo, Brazil.
  • Campos-Staffico AM; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States.
  • Nadruz W; Cardiology Division, Clinics Hospital, Unicamp, Campinas, Sao Paulo, Brazil.
  • Quinaglia T; Massachussets General Hospital, Harvard University, Boston, MA, United States.
  • Sposito AC; Laboratory of Atherosclerosis and Vascular Biology, University of Campinas (Unicamp), Campinas, Sao Paulo, Brazil.
Front Clin Diabetes Healthc ; 4: 1243530, 2023.
Article em En | MEDLINE | ID: mdl-37822556
Sodium glucose cotransporter 2 inhibitors (SGLT2) have been increasingly pursued as a promising target for addressing residual cardiovascular risk. Prior trials demonstrated that SGLT2i not only promotes glucose-lowering, but also improves endothelial dysfunction, adiposity, fluid overload, and insulin sensitivity thus contributing to hemodynamic changes implicated in its cardiorenal benefits. The mechanisms in the effect of SGLT2i on blood pressure and their potential role in preventing cardiovascular events are hereby revised.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Clin Diabetes Healthc Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Clin Diabetes Healthc Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça